The largest provider of private support of liver disease research and training in the United States is actually the American Association for the Study of Liver Diseases (AASLD). Recently, this organization announced its combined investment of over $2.2 million in...
Liver Disease
Category
Dicerna Inks Drug Discovery and Development Agreement Targeting Liver Disease
Dicerna’s GalXC RNAi platform technology was involved in yet another big pharma collaborative drug discovery and development deal. Just weeks after the announcement of a $1.67 billion deal with Roche, now Novo Nordisk inked an agreement to discover and develop novel...
Mirum Pharma Granted Breakthrough Therapy Designation for Maralixibat for Pruritus Associated with Alagille Syndrome
Mirum Pharmaceuticals announced the U.S. FDA has granted Breakthrough Therapy Designation for maralixibat for the treatment of pruritus associated with Alagille syndrome (ALGS) in patients 1 year of age and older. The Breakthrough Therapy Designation of...
Clinical Investigation Site Summary: Cullman Clinical Trials Treating Nonalcoholic Steatohepatitis (NASH)
TrialSite News is on a mission to procure and provide to our readers the necessary knowledge to making decisions about their clinical trial participation and quality of care. In doing so, we have started a research project covering a multitude of clinical...
Clinical Investigation Site Summary: Integrity Clinical Research Treating Nonalcoholic Steatohepatitis (NASH)
In an ongoing effort to provide our readers the most relevant and useful news regarding clinical research, we are covering Integrity Clinical Research in Doral, FL. They are one of over 300 clinical investigation sites involved in a new treatment for Nonalcoholic...
Clinical Investigation Site Summary: Fresno Clinical Research Center Treating Nonalcoholic Steatohepatitis (NASH)
TrialSite News has embarked on a research project unlike any other—inquiring a solid, transparent and patient-centric summary of clinical research sites involved in the clinical trial industry. Below we have provided a review of Fresno Clinical Research Center, a...
University of Manitoba Commences Study to Understand why NAFLD Rates so High in this Part of Canada
The University of Manitoba Department of Internal Medicine’s Section of Hepatology is undertaking a five-year study to identify why Nonalcoholic fatty liver disease (NAFLD) is the most prevalent disease in Canada, with the Canadian Liver Foundation estimates 25% of...
Terns Pharmaceuticals Granted Fast Track Designation from U.S. FDA for TERN-101 for the Treatment of NASH
Terns Pharmaceuticals announced the U.S. FDA has granted Fast Track status to their investigational farnesoid X receptor (FXR) agonist, TERN-101, for the treatment of non-alcoholic steatohepatitis (NASH). A completed phase 1 trial demonstrated clinical pharmacokinetic...
Clinical Investigation Site Summary: The Institute for Liver Health Treating Nonalcoholic Steatohepatitis (NASH)
As part of Trialsite News’ ongoing summary of clinical research sites across multiple facets of the clinical trial industry, we have included below a cursory review of The Institute for Liver Health, a clinical investigation site studying the treatment of Nonalcoholic...
Breakthrough Liver Disease Detection Technology Developed by HISKY MED & Tsinghua University Coming to America
Wuxi Hisky Medical Technologies Co Ltd, a Chinese medical device venture, has launched an innovative, non-invasive liver disease detection product. Called iLivTouch, the company uses multichannel imaging-guided transient elastography, a breakthrough in related medical...
The Emerging NASH Crisis
R&D Points Toward NASH In late 2018, Bay Area-based Gilead, known for HIV and Hepatitis C drugs, structured a deal worth up to $1.5 billion with Cambridge, MA-based Scholar Rock Holdings Corporation. Gilead would immediately pay $80 million in upfront payments...
Cincinnati Children’s Hospital Researchers Bioengineer Human Liver Disease in Lab to Find New Treatment
University of Cincinnati researchers have successfully bioengineered human live organoids that faithfully mimic key features of fatal liver disease in the laboratory. This allowed them to uncover underlying disease biology in the organoids and test a potential therapy...
Gilead Reports Phase 3 STELLAR-3 of Selonsertib for Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis Fails to Meet Endpoints
Gilead announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib for patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis (NASH), did not meet the pre-specified week 48...
Arrowhead Pharma Moves ARO-AAT Into Phase 2/3 for Alpha-1 Liver Disease Following FDA Clearance
Arrowhead Pharmaceuticals received clearance from the U.S. FDA to proceed with an adaptive Phase 2/3 trial of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic...
Powerful New Liver Disease Research Network Spans Across Regions
SC Liver Research Consortium (SC Liver) and Perspectum Diagnostics have developed a major US-based clinical network to provide clinical trials services that support the development of drugs for liver disorders reports a recent press release. SC Liver is an...
Galmed’s Treatment for NASH and Fibrosis Headed for Phase 3 Following Successful End-of-Phase 2 Meeting With FDA
Galmed Pharmaceuticals successfully completed its End-of-Phase 2 meeting with the FDA discussing the future development of Aramchol. A general agreement was reached on key aspects of the Phase 3/4 development and registration plan for Aramchol and on the pivotal...
Clinical Trial Immunotherapy Treatment for Two Autoimmune Liver Diseases
Orbsen Therapeutics, a biotech company focused on the development and commercialization of first-in-class stromal cell immunotherapies, announced its second generation immunotherapy ORBCEL-C™ is being administered to patients participating in MERLIN, a multi-site...
Dicerna Reports Updated PHYOX-1 Data; PHYOX-2 now Enrolling Patients with Primary Hyperoxaluria Type 1 and Type 2
Dicerna Pharmaceuticals presented updated data from its ongoing PHYOX1 Phase 1 clinical trial evaluating DCR-PHXC, the Company’s lead GalXC product candidate. The data was presented in a poster at the German Society of Pediatric Nephrology 50th Annual Meeting in...
Pfizer Invests $51 Million to Access Gene Therapy Platform for Liver Disorders
FINSMES reports Pfizer has invested $51 million for a 15% stake in Vivet Therapeutics, a France-based gene therapy venture dedicated to developing inherited liver disorder treatments. Pfizer secured an exclusive option to buy all outstanding shares. Pfizer’s Monika...
Univ. of Birmingham UK Trials a New Stromal Cell Immunotherapy for Chronic Liver Disease
The University of Birmingham, UK has launched a clinical trial that could lead to ground-breaking new ways to treat patients with two types of chronic liver disease including 1) Primary Sclerosing Cholangitis (PSC) or 2) Autoimmune Hepatitis (AIH). The English...